HC Wainwright & Co. Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has reaffirmed its Buy rating on Gossamer Bio (NASDAQ:GOSS) and increased its price target from $5.00 to $10.00. Gossamer Bio's shares have risen 7.06% in the last 24 hours to $0.91. The new price target suggests a potential upside of 998.9%. Gossamer Bio is a clinical-stage biopharmaceutical company with products in development for various diseases, including PAH, inflammatory bowel disease, oncology indications, and eosinophilic asthma.
January 08, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Gossamer Bio and raises the price target to $10.00, indicating a significant potential increase from the current price of $0.91.
The reaffirmation of the Buy rating and the substantial increase in the price target by HC Wainwright & Co. are strong positive signals for investors, suggesting confidence in Gossamer Bio's future performance. The recent 7.06% increase in share price reflects immediate market reaction, but the new price target implies a much larger potential upside, which could drive further short-term interest and investment in the stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100